We are live on ! Find out more
PALI icon

Palisade Bio
PALI

9 hedge funds and large institutions have $485K invested in Palisade Bio in 2020 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

29% more funds holding

Funds holding: 7 → 9 (+2)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

8% less capital invested

Capital invested by funds: $527K → $485K (-$42K)

Holders
9
Holders Change
+2
Holders Change %
+28.57%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$63K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$24K
3
Northern Trust
Northern Trust
Illinois
+$12K
4
TRCT
Tower Research Capital (TRC)
New York
+$12K
5
UBS Group
UBS Group
Switzerland
+$6K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$229K
2
Renaissance Technologies
Renaissance Technologies
New York
-$63K
3
HighTower Advisors
HighTower Advisors
Illinois
-$33K

PALI Hedge Fund Activity: Q4 2020 in Review

9 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q4 2020, worth a combined $485K — down 8% from $527K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new PALI positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Virtu Financial, adding an estimated $63K. The largest seller was Sabby Management, exiting entirely with an estimated $229K sold.

  • 9 institutional investors held Palisade Bio (PALI) as of Q4 2020, up from 7 in Q3 2020.
  • Funds reported $485K of Palisade Bio stock for Q4 2020, down 8% quarter-over-quarter.
  • 3 funds opened new Palisade Bio positions in Q4 2020 and 1 closed out, a net change of +2 holders.
  • The largest Palisade Bio buyer in Q4 2020 was Virtu Financial, an estimated $63K added.
  • The largest Palisade Bio seller in Q4 2020 was Sabby Management, an estimated $229K sold.

Based on aggregated 13F filings for Q4 2020.